Ligand Pharmaceuticals Incorporated (LGND)
USD 99.8
(-3.21%)
USD 99.8
(-3.21%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.78 Million USD | -119.14% |
| 2022 | 87.7 Million USD | -72.31% |
| 2021 | 316.73 Million USD | -22.16% |
| 2020 | 406.91 Million USD | 212.22% |
| 2019 | -362.6 Million USD | -341.75% |
| 2018 | -82.08 Million USD | -458.95% |
| 2017 | 22.86 Million USD | -68.18% |
| 2016 | 71.86 Million USD | 1294.57% |
| 2015 | 5.15 Million USD | -82.17% |
| 2014 | 28.9 Million USD | 520.76% |
| 2013 | -6.87 Million USD | -143.22% |
| 2012 | 15.89 Million USD | -64.43% |
| 2011 | 44.69 Million USD | 62.3% |
| 2010 | 27.53 Million USD | 10.89% |
| 2009 | 24.83 Million USD | 200.36% |
| 2008 | -24.74 Million USD | 66.85% |
| 2007 | -74.65 Million USD | 37.0% |
| 2006 | -118.49 Million USD | -211.62% |
| 2005 | 106.16 Million USD | 29.93% |
| 2004 | 81.7 Million USD | -28.01% |
| 2003 | 113.5 Million USD | -1.23% |
| 2002 | 114.91 Million USD | -5.33% |
| 2001 | 121.38 Million USD | -3.63% |
| 2000 | 125.95 Million USD | 13.58% |
| 1999 | 110.9 Million USD | 82.1% |
| 1998 | 60.9 Million USD | 851.85% |
| 1997 | -8.1 Million USD | -137.16% |
| 1996 | 21.8 Million USD | -39.94% |
| 1995 | 36.3 Million USD | 505.0% |
| 1994 | 6 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -43.89 Million USD | -161.47% |
| 2024 Q2 | -10.55 Million USD | 75.95% |
| 2023 Q1 | -193.98 Million USD | -321.19% |
| 2023 Q3 | -12.94 Million USD | 93.76% |
| 2023 Q4 | -16.78 Million USD | -29.68% |
| 2023 FY | -16.78 Million USD | -119.14% |
| 2023 Q2 | -207.37 Million USD | -6.9% |
| 2022 FY | 87.7 Million USD | -72.31% |
| 2022 Q2 | 139.33 Million USD | -14.75% |
| 2022 Q1 | 163.44 Million USD | -48.4% |
| 2022 Q4 | 87.7 Million USD | -20.1% |
| 2022 Q3 | 109.77 Million USD | -21.22% |
| 2021 FY | 316.73 Million USD | -22.16% |
| 2021 Q1 | 328.07 Million USD | -19.38% |
| 2021 Q2 | 295.77 Million USD | -9.84% |
| 2021 Q3 | 307.15 Million USD | 3.85% |
| 2021 Q4 | 316.73 Million USD | 3.12% |
| 2020 Q4 | 406.91 Million USD | 21042.36% |
| 2020 Q3 | -1.94 Million USD | 99.46% |
| 2020 Q2 | -360.2 Million USD | -22.36% |
| 2020 Q1 | -294.37 Million USD | 18.82% |
| 2020 FY | 406.91 Million USD | 212.22% |
| 2019 FY | -362.6 Million USD | -341.75% |
| 2019 Q2 | -680.75 Million USD | 13.27% |
| 2019 Q3 | -468.15 Million USD | 31.23% |
| 2019 Q4 | -362.6 Million USD | 22.55% |
| 2019 Q1 | -784.94 Million USD | -856.27% |
| 2018 Q3 | 700.42 Million USD | 564.95% |
| 2018 FY | -82.08 Million USD | -458.95% |
| 2018 Q4 | -82.08 Million USD | -111.72% |
| 2018 Q2 | -150.64 Million USD | -185.34% |
| 2018 Q1 | 176.52 Million USD | 671.92% |
| 2017 Q2 | 46 Million USD | -77.57% |
| 2017 Q1 | 205.1 Million USD | 185.42% |
| 2017 FY | 22.86 Million USD | -68.18% |
| 2017 Q4 | 22.86 Million USD | -87.89% |
| 2017 Q3 | 188.81 Million USD | 310.45% |
| 2016 Q3 | 86 Million USD | -41.1% |
| 2016 Q1 | 91.45 Million USD | 1674.73% |
| 2016 Q4 | 71.86 Million USD | -16.44% |
| 2016 FY | 71.86 Million USD | 1294.57% |
| 2016 Q2 | 146.01 Million USD | 59.66% |
| 2015 Q1 | 32.8 Million USD | 13.47% |
| 2015 Q3 | 109.18 Million USD | 475.91% |
| 2015 FY | 5.15 Million USD | -82.17% |
| 2015 Q2 | 18.95 Million USD | -42.2% |
| 2015 Q4 | 5.15 Million USD | -95.28% |
| 2014 Q2 | -19.32 Million USD | -168.16% |
| 2014 Q3 | 7.38 Million USD | 138.18% |
| 2014 Q4 | 28.9 Million USD | 291.68% |
| 2014 FY | 28.9 Million USD | 520.76% |
| 2014 Q1 | -7.2 Million USD | -4.92% |
| 2013 Q2 | 9.64 Million USD | -29.42% |
| 2013 Q3 | 9.1 Million USD | -5.63% |
| 2013 Q1 | 13.66 Million USD | -14.02% |
| 2013 Q4 | -6.87 Million USD | -175.46% |
| 2013 FY | -6.87 Million USD | -143.22% |
| 2012 Q2 | 20.63 Million USD | 5.3% |
| 2012 Q3 | 30.62 Million USD | 48.42% |
| 2012 Q4 | 15.89 Million USD | -48.09% |
| 2012 FY | 15.89 Million USD | -64.43% |
| 2012 Q1 | 19.59 Million USD | -15.71% |
| 2011 FY | 44.69 Million USD | 62.3% |
| 2011 Q2 | 36.53 Million USD | 4.85% |
| 2011 Q1 | 34.84 Million USD | 78.64% |
| 2011 Q4 | 23.24 Million USD | -64.65% |
| 2011 Q3 | 65.76 Million USD | 80.01% |
| 2010 Q4 | 19.5 Million USD | -51.11% |
| 2010 Q3 | 39.89 Million USD | -12.81% |
| 2010 Q2 | 45.75 Million USD | 31.21% |
| 2010 Q1 | 34.87 Million USD | 71.5% |
| 2010 FY | 27.53 Million USD | 10.89% |
| 2009 Q4 | 20.33 Million USD | -61.13% |
| 2009 Q1 | 53.48 Million USD | 316.14% |
| 2009 Q2 | 54.38 Million USD | 1.67% |
| 2009 Q3 | 52.31 Million USD | -3.81% |
| 2009 FY | 24.83 Million USD | 200.36% |
| 2008 FY | -24.74 Million USD | 66.85% |
| 2008 Q1 | -57.9 Million USD | 22.44% |
| 2008 Q2 | -27.93 Million USD | 51.76% |
| 2008 Q3 | -10.91 Million USD | 60.93% |
| 2008 Q4 | -24.74 Million USD | -126.76% |
| 2007 FY | -74.65 Million USD | 37.0% |
| 2007 Q1 | -400.11 Million USD | -237.67% |
| 2007 Q2 | -100.36 Million USD | 74.92% |
| 2007 Q3 | -66.6 Million USD | 33.64% |
| 2007 Q4 | -74.65 Million USD | -12.09% |
| 2006 Q3 | 132.4 Million USD | 28.3% |
| 2006 Q4 | -118.49 Million USD | -189.5% |
| 2006 Q1 | 96.64 Million USD | -8.97% |
| 2006 Q2 | 103.2 Million USD | 6.78% |
| 2006 FY | -118.49 Million USD | -211.62% |
| 2005 Q1 | 123.13 Million USD | 50.7% |
| 2005 FY | 106.16 Million USD | 29.93% |
| 2005 Q2 | 141.21 Million USD | 14.69% |
| 2005 Q3 | 123.43 Million USD | -12.59% |
| 2005 Q4 | 106.16 Million USD | -13.99% |
| 2004 FY | 81.7 Million USD | -28.01% |
| 2004 Q4 | 81.7 Million USD | -36.25% |
| 2004 Q3 | 128.16 Million USD | 0.06% |
| 2004 Q2 | 128.09 Million USD | 18.57% |
| 2004 Q1 | 108.03 Million USD | -4.82% |
| 2003 Q1 | 144.37 Million USD | 25.64% |
| 2003 Q3 | 82.24 Million USD | -41.43% |
| 2003 Q2 | 140.42 Million USD | -2.74% |
| 2003 FY | 113.5 Million USD | -1.23% |
| 2003 Q4 | 113.5 Million USD | 38.0% |
| 2002 Q1 | 37.81 Million USD | -68.84% |
| 2002 FY | 114.91 Million USD | -5.33% |
| 2002 Q3 | -7.21 Million USD | 58.41% |
| 2002 Q4 | 114.91 Million USD | 1692.05% |
| 2002 Q2 | -17.35 Million USD | -145.89% |
| 2001 FY | 121.38 Million USD | -3.63% |
| 2001 Q2 | 125.8 Million USD | 9.06% |
| 2001 Q3 | 121.85 Million USD | -3.14% |
| 2001 Q4 | 121.38 Million USD | -0.39% |
| 2001 Q1 | 115.36 Million USD | -8.41% |
| 2000 FY | 125.95 Million USD | 13.58% |
| 2000 Q3 | 112.12 Million USD | 12.34% |
| 2000 Q1 | 97.45 Million USD | -12.12% |
| 2000 Q2 | 99.81 Million USD | 2.42% |
| 2000 Q4 | 125.95 Million USD | 12.34% |
| 1999 Q4 | 110.9 Million USD | -15.73% |
| 1999 Q2 | 87.9 Million USD | 5.4% |
| 1999 Q1 | 83.4 Million USD | 36.95% |
| 1999 FY | 110.9 Million USD | 82.1% |
| 1999 Q3 | 131.6 Million USD | 49.72% |
| 1998 Q3 | 27.9 Million USD | 6.9% |
| 1998 Q1 | 28.7 Million USD | 454.32% |
| 1998 FY | 60.9 Million USD | 851.85% |
| 1998 Q4 | 60.9 Million USD | 118.28% |
| 1998 Q2 | 26.1 Million USD | -9.06% |
| 1997 Q3 | 39.2 Million USD | 6.81% |
| 1997 FY | -8.1 Million USD | -137.16% |
| 1997 Q4 | -8.1 Million USD | -120.66% |
| 1997 Q2 | 36.7 Million USD | 19.16% |
| 1997 Q1 | 30.8 Million USD | 41.28% |
| 1996 Q2 | 42.7 Million USD | 16.03% |
| 1996 Q4 | 21.8 Million USD | -50.23% |
| 1996 Q1 | 36.8 Million USD | 1.38% |
| 1996 Q3 | 43.8 Million USD | 2.58% |
| 1996 FY | 21.8 Million USD | -39.94% |
| 1995 FY | 36.3 Million USD | 505.0% |
| 1995 Q3 | 38.7 Million USD | 0.0% |
| 1995 Q1 | - USD | -100.0% |
| 1995 Q4 | 36.3 Million USD | -6.2% |
| 1994 Q4 | 6 Million USD | 328.57% |
| 1994 Q2 | 2.8 Million USD | 100.0% |
| 1994 Q3 | 1.4 Million USD | -50.0% |
| 1994 FY | 6 Million USD | 0.0% |
| 1994 Q1 | 1.4 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 69.987% |
| Alkermes plc | -166.73 Million USD | 89.931% |
| Agenus Inc. | 274.13 Million USD | 106.124% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.898% |
| Aptorum Group Limited | 1.35 Million USD | 1337.173% |
| Ardelyx, Inc. | 34.51 Million USD | 148.647% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 492.266% |
| Bicycle Therapeutics plc | -481.46 Million USD | 96.513% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 146.426% |
| ChromaDex Corporation | -24.04 Million USD | 30.185% |
| Chimerix, Inc. | -25.51 Million USD | 34.205% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 340.942% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 29.092% |
| CRISPR Therapeutics AG | -150.84 Million USD | 88.87% |
| Precision BioSciences, Inc. | -85.41 Million USD | 80.343% |
| Dyadic International, Inc. | -6.37 Million USD | -163.229% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -5.372% |
| Fortress Biotech, Inc. | 7.66 Million USD | 319.035% |
| Lantern Pharma Inc. | -21.7 Million USD | 22.643% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 84.811% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -96.519% |
| Incyte Corporation | -3.17 Billion USD | 99.471% |
| IO Biotech, Inc. | -140.69 Million USD | 88.067% |
| Jaguar Health, Inc. | 29.39 Million USD | 157.123% |
| Novavax, Inc. | -298.29 Million USD | 94.372% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 414.577% |
| Opthea Limited | 28.15 Million USD | 159.625% |
| ContextLogic Inc. | -232 Million USD | 92.763% |
| MiMedx Group, Inc. | -33.9 Million USD | 50.476% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 264.679% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -624.592% |
| NextCure, Inc. | -6.47 Million USD | -159.21% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 66.755% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -163.192% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 238.03% |
| Vaxcyte, Inc. | -368.22 Million USD | 95.441% |
| PDS Biotechnology Corporation | -32.7 Million USD | 48.671% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 197.17% |
| Pharming Group N.V. | 109.8 Million USD | 115.29% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 3.489% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 90.419% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 9.346% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 9.346% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -136.465% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -186.502% |
| Acelyrin, Inc. | -216.9 Million USD | 92.26% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -199.255% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -873.84% |
| Summit Therapeutics Inc. | 34.67 Million USD | 148.42% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -146.788% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1064.885% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 90.906% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 78.323% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -176.955% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 16927.872% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 2773.408% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 85.656% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 90.02% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 115.143% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -121.024% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 86.997% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 343.509% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 93.073% |
| Immix Biopharma, Inc. | -17.5 Million USD | 4.117% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 94.699% |
| MEI Pharma, Inc. | -3.7 Million USD | -353.144% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 234.194% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 110.38% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 160.407% |
| Fortress Biotech, Inc. | 7.66 Million USD | 319.035% |
| Precigen, Inc. | -481 Thousand USD | -3390.437% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 219.232% |
| AlloVir, Inc. | -62.69 Million USD | 73.22% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 69.812% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 127.226% |
| ImmuCell Corporation | 10.99 Million USD | 252.758% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 89.108% |
| Onconetix, Inc. | 5.33 Million USD | 414.906% |
| PureTech Health plc | -167.19 Million USD | 89.959% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 44.882% |
| Elevation Oncology, Inc. | -19.11 Million USD | 12.182% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -242.004% |
| Seer, Inc. | -4.24 Million USD | -295.967% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 30.154% |
| Innoviva, Inc. | 255.56 Million USD | 106.569% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 69.947% |
| ESSA Pharma Inc. | -33.62 Million USD | 50.065% |
| GlycoMimetics, Inc. | -40.98 Million USD | 59.036% |
| GT Biopharma, Inc. | -1.02 Million USD | -1544.368% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 75.231% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 127.407% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 87.478% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -21.168% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 41.85% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -22186.086% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 45.6% |
| Aptose Biosciences Inc. | -8.19 Million USD | -104.872% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -436.558% |
| Soligenix, Inc. | -4.95 Million USD | -239.062% |
| Century Therapeutics, Inc. | 847 Thousand USD | 2082.172% |
| Kura Oncology, Inc. | -20.11 Million USD | 16.547% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 58.977% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -99.917% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 1021.614% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -425.149% |
| Autolus Therapeutics plc | -186.59 Million USD | 91.003% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 65.948% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 93.912% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 148.993% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 110.214% |
| GRI Bio, Inc. | -1.79 Million USD | -835.842% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -86.897% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 49.517% |
| IGM Biosciences, Inc. | -72.6 Million USD | 76.877% |
| INmune Bio, Inc. | -25.41 Million USD | 33.93% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 111.122% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 66.859% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -3.321% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -481.956% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 144.164% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 59.235% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 152.655% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 104.442% |
| Verastem, Inc. | -37.27 Million USD | 54.963% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -85.044% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 67.628% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -10.928% |
| Histogen Inc. | -7.48 Million USD | -124.242% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 22.298% |
| Surrozen, Inc. | -32.66 Million USD | 48.601% |
| Organovo Holdings, Inc. | -1.5 Million USD | -1014.068% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -299.406% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 188.549% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 741.781% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 503.97% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -100.319% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 61.353% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -15.176% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 94.7% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -2225.153% |
| Apollomics, Inc. | -27.39 Million USD | 38.715% |
| Amarin Corporation plc | -191.04 Million USD | 91.212% |
| Mesoblast Limited | 55.96 Million USD | 130.0% |
| Turnstone Biologics Corp. | -14.58 Million USD | -15.119% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 33.619% |
| Synaptogenix, Inc. | -28.66 Million USD | 41.423% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -1693.697% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 134.452% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1847.479% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -131.06% |
| Exelixis, Inc. | -73.05 Million USD | 77.017% |
| Better Therapeutics, Inc. | -860 Thousand USD | -1852.209% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 30.084% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 93.044% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2380.91% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -125.715% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 1438.836% |
| Gritstone bio, Inc. | 39.49 Million USD | 142.515% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 80.037% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -537.846% |
| Avid Bioservices, Inc. | 169.72 Million USD | 109.892% |
| Insmed Incorporated | 721.62 Million USD | 102.327% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -83.657% |
| MediWound Ltd. | -5.32 Million USD | -215.464% |
| OmniAb, Inc. | 9.2 Million USD | 282.43% |
| Alector, Inc. | -35.63 Million USD | 52.889% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 119.529% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -240.686% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 226.815% |
| Zai Lab Limited | -775 Million USD | 97.834% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 104.93% |
| Aura Biosciences, Inc. | -21.52 Million USD | 22.002% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 79.645% |
| Immunic, Inc. | -45.34 Million USD | 62.971% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 91.311% |
| Veracyte, Inc. | -203.82 Million USD | 91.763% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 102.63% |
| FibroGen, Inc. | 56.76 Million USD | 129.575% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 288.535% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -493.863% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -710.926% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.366% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -402.514% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 89.884% |
| TG Therapeutics, Inc. | 17.86 Million USD | 193.993% |
| Galecto, Inc. | -21.21 Million USD | 20.866% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 29.413% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 101.07% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 31.395% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -45.902% |
| XBiotech Inc. | -200.02 Million USD | 91.606% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 80.037% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 470.782% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 52.389% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 78.258% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 395.01% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 90.148% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 81.825% |
| Vaxxinity, Inc. | 10.13 Million USD | 265.703% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 102.28% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -55.922% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 74.545% |
| NexImmune, Inc. | -3.13 Million USD | -435.766% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -386.261% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -11.101% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 38.048% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -87.042% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -13377.022% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 58.619% |
| Ainos, Inc. | 4.07 Million USD | 511.704% |
| Pluri Inc. | 22.82 Million USD | 173.542% |
| Prothena Corporation plc | -608.34 Million USD | 97.24% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 85.863% |
| Celularity Inc. | 65.19 Million USD | 125.754% |
| Rallybio Corporation | -24.1 Million USD | 30.342% |
| Cue Biopharma, Inc. | -33.81 Million USD | 50.356% |
| MeiraGTx Holdings plc | -40.3 Million USD | 58.342% |
| Omeros Corporation | 331.17 Million USD | 105.07% |
| Humacyte, Inc. | -22.48 Million USD | 25.336% |
| Immunocore Holdings plc | -358.59 Million USD | 95.318% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 31.683% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 45.668% |
| Blueprint Medicines Corporation | 702.83 Million USD | 102.389% |
| CalciMedica, Inc. | -5.53 Million USD | -203.599% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 91.08% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -64.372% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 58.066% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 49.511% |
| Pulmatrix, Inc. | -10.41 Million USD | -61.169% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -180.893% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 55.983% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 84.929% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 71.992% |
| Cytokinetics, Incorporated | 642.37 Million USD | 102.614% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -188.322% |
| Nutriband Inc. | -251.65 Thousand USD | -6571.382% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 50.793% |
| Vor Biopharma Inc. | 4.3 Million USD | 490.442% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.722% |
| Evogene Ltd. | -19.63 Million USD | 14.49% |
| ProKidney Corp. | -56.23 Million USD | 70.145% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 65.506% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -81.754% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 101.231% |
| CorMedix Inc. | -43.05 Million USD | 61.003% |
| BioLineRx Ltd. | 7.33 Million USD | 328.858% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 38.871% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 136.382% |
| Atai Life Sciences N.V. | -28.55 Million USD | 41.211% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 852.691% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 26.416% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 194.666% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 77.637% |
| MediciNova, Inc. | -50.78 Million USD | 66.94% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 78.696% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -74534.363% |
| GeoVax Labs, Inc. | -6.45 Million USD | -160.19% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 91.598% |
| Biomea Fusion, Inc. | -166.57 Million USD | 89.921% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 90.619% |
| Mereo BioPharma Group plc | -51.46 Million USD | 67.38% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 82.298% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 94.285% |
| Absci Corporation | -72.59 Million USD | 76.874% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 467.696% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 92.839% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 82.179% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 82.456% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 57.032% |
| Allakos Inc. | -24.97 Million USD | 32.777% |
| Imunon, Inc. | -4.21 Million USD | -298.424% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -13.885% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 87.6% |
| BioAtla, Inc. | -109.01 Million USD | 84.599% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 2380.91% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -1687.966% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 240.306% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 20.818% |
| XOMA Corporation | -29 Million USD | 42.107% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -1.383% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -86.213% |
| aTyr Pharma, Inc. | -7.44 Million USD | -125.386% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 86.53% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 91.935% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 79.47% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 81.901% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -1854.063% |
| Akari Therapeutics, Plc | -3.84 Million USD | -336.645% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1134.513% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.216% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1313.055% |
| UroGen Pharma Ltd. | 4.39 Million USD | 482.35% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 114.795% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 23430.369% |
| Orgenesis Inc. | 21.78 Million USD | 177.07% |
| Entera Bio Ltd. | -10.62 Million USD | -57.955% |
| GH Research PLC | -78.07 Million USD | 78.497% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 24.672% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 37.023% |
| Xencor, Inc. | 29.64 Million USD | 156.635% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -752.315% |
| Replimune Group, Inc. | 1.41 Million USD | 1289.023% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -6755.227% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 86.719% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -1313.055% |
| Portage Biotech Inc. | -4.98 Million USD | -237.061% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -74534.363% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 74.609% |
| OncoCyte Corporation | -6.56 Million USD | -155.813% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 1970.822% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -268.532% |
| Purple Biotech Ltd. | -14.13 Million USD | -18.751% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 29.327% |
| scPharmaceuticals Inc. | -6.54 Million USD | -156.516% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -0.58% |
| HilleVax, Inc. | -165.48 Million USD | 89.855% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -561.505% |
| Tharimmune, Inc. | -10.93 Million USD | -53.53% |
| Genprex, Inc. | -6.73 Million USD | -149.183% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 95.448% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 81.021% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -1098.358% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -406.158% |
| OKYO Pharma Limited | -826.84 Thousand USD | -1930.482% |
| Savara Inc. | 153 Thousand USD | 11073.203% |
| Curis, Inc. | -23.88 Million USD | 29.715% |
| Daré Bioscience, Inc. | -5.15 Million USD | -225.5% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -2063.497% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -170.441% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 1516.793% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.255% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 236.07% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 97.24% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 90.954% |
| Erasca, Inc. | -37.21 Million USD | 54.888% |
| bluebird bio, Inc. | 108.57 Million USD | 115.464% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1203.602% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 104.433% |
| DBV Technologies S.A. | -126.98 Million USD | 86.779% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -1203.602% |
| Moderna, Inc. | -2.9 Billion USD | 99.422% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -62.181% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -54.481% |
| Molecular Templates, Inc. | 707 Thousand USD | 2474.682% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 46.482% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 104.844% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 79.541% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 81.697% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 47.977% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 51.161% |
| MacroGenics, Inc. | -66.98 Million USD | 74.936% |
| RenovoRx, Inc. | -1.17 Million USD | -1331.287% |
| Adicet Bio, Inc. | -138.78 Million USD | 87.903% |
| Prime Medicine, Inc. | -27.94 Million USD | 39.913% |
| Aditxt, Inc. | 18.12 Million USD | 192.65% |
| Adagene Inc. | -87.62 Million USD | 80.84% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -303.056% |
| Quantum-Si incorporated | -118.55 Million USD | 85.839% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 146.63% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -124.626% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 65.39% |
| SciSparc Ltd. | -2.06 Million USD | -713.027% |
| Vericel Corporation | 1.27 Million USD | 1414.722% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -40.005% |
| Minerva Neurosciences, Inc. | 41 Million USD | 140.945% |
| Generation Bio Co. | 31.44 Million USD | 153.387% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 90.426% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 45.707% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 114.4% |
| Invivyd, Inc. | -198.47 Million USD | 91.541% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 81.401% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -600.216% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 76.283% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -145.993% |
| 2seventy bio, Inc. | 181.71 Million USD | 109.239% |
| ADMA Biologics, Inc. | 90.06 Million USD | 118.641% |
| Clene Inc. | 3.34 Million USD | 602.665% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -84.846% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 21.952% |
| GeoVax Labs, Inc. | -6.45 Million USD | -160.19% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 95.121% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 35.426% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 109.45% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -310.332% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 435.646% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -222.308% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 87.116% |
| Evaxion Biotech A/S | 5.28 Million USD | 417.562% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 85.085% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 87.211% |
| Trevena, Inc. | 2.25 Million USD | 843.534% |
| Surrozen, Inc. | -32.66 Million USD | 48.601% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 67.406% |
| Cingulate Inc. | 3.08 Million USD | 644.623% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -471.638% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 333.602% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -80.697% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 78.835% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 87.228% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 84.093% |
| Clearmind Medicine Inc. | -3.94 Million USD | -325.832% |
| Kronos Bio, Inc. | -36.05 Million USD | 53.434% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 278.436% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1251.409% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 69.056% |
| Statera Biopharma, Inc. | 14.41 Million USD | 216.458% |
| ImmunityBio, Inc. | 618.22 Million USD | 102.716% |
| Korro Bio, Inc. | -132.94 Million USD | 87.371% |
| Kineta, Inc. | -4.54 Million USD | -269.72% |
| BioVie Inc. | -17.73 Million USD | 5.32% |
| Codexis, Inc. | -43.27 Million USD | 61.2% |
| Celularity Inc. | 65.19 Million USD | 125.754% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -429.789% |
| Celcuity Inc. | 6.78 Million USD | 347.497% |
| Virax Biolabs Group Limited | -3.36 Million USD | -398.938% |
| Cibus, Inc. | -8.07 Million USD | -107.836% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -296.997% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 467.374% |
| IN8bio, Inc. | -16.38 Million USD | -2.441% |
| Kodiak Sciences Inc. | -103.87 Million USD | 83.837% |
| Annexon, Inc. | -193.75 Million USD | 91.335% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 46736.111% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 4.057% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -377.911% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 101.592% |
| Eyenovia, Inc. | 1.25 Million USD | 1433.834% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 162.401% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -417.7% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 49.502% |
| Arcellx, Inc. | -296.95 Million USD | 94.346% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 13.929% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 71.484% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 18.999% |
| Moolec Science SA | 117.61 Thousand USD | 14374.418% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 56.278% |
| Geron Corporation | 14.76 Million USD | 213.739% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 55.723% |
| Royalty Pharma plc | 5.65 Billion USD | 100.297% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 88.128% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -140.206% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -213.061% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 88.07% |
| Humacyte, Inc. | -22.48 Million USD | 25.336% |
| Structure Therapeutics Inc. | -124.33 Million USD | 86.497% |
| 89bio, Inc. | -289.05 Million USD | 94.192% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 33.488% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -841.615% |
| Genelux Corporation | -6.89 Million USD | -143.354% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 45.945% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 120.083% |
| Notable Labs, Ltd. | -9.77 Million USD | -71.737% |
| Liquidia Corporation | -80.17 Million USD | 79.06% |
| Mustang Bio, Inc. | -3.73 Million USD | -349.384% |
| Immunovant, Inc. | -635.22 Million USD | 97.357% |
| Quantum-Si incorporated | -118.55 Million USD | 85.839% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 4.412% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -305.238% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 309.157% |
| Acasti Pharma Inc. | -23 Million USD | 27.02% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -398.6% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -3.321% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 87.811% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -438.737% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 24.483% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 9.586% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 90.082% |
| PepGen Inc. | -60.67 Million USD | 72.327% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 26.928% |
| United Therapeutics Corporation | -507.7 Million USD | 96.693% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 12.219% |
| Solid Biosciences Inc. | -47.75 Million USD | 64.84% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -1847.479% |
| Immuneering Corporation | -54.94 Million USD | 69.443% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -299.406% |
| Silo Pharma, Inc. | -3.52 Million USD | -376.377% |
| Belite Bio, Inc | -87.27 Million USD | 80.762% |
| XOMA Corporation | -29 Million USD | 42.107% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 76.252% |
| Bionomics Limited | 227 Million USD | 107.396% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 85.562% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -562.811% |
| uniQure N.V. | -102.95 Million USD | 83.692% |
| Cassava Sciences, Inc. | -121.13 Million USD | 86.14% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -303.056% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 140.998% |
| Forte Biosciences, Inc. | -11.96 Million USD | -40.365% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -442.596% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 15938.679% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -417.7% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 288.535% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -126.389% |
| Altimmune, Inc. | -134.48 Million USD | 87.516% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 108.477% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -562.811% |
| Compugen Ltd. | -12.9 Million USD | -30.107% |
| Peak Bio, Inc. | 10.34 Million USD | 262.367% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -5832.509% |
| Benitec Biopharma Inc. | -50.58 Million USD | 66.808% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 83.909% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 185.462% |
| Zura Bio Limited | -99.8 Million USD | 83.178% |
| PolyPid Ltd. | 6.17 Million USD | 372.107% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 122.651% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 185.462% |
| Instil Bio, Inc. | 75.35 Million USD | 122.279% |
| argenx SE | -2.02 Billion USD | 99.172% |
| Immunome, Inc. | -97.02 Million USD | 82.697% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 25.366% |
| Verona Pharma plc | -220.44 Million USD | 92.384% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 76.598% |
| Shattuck Labs, Inc. | -121.42 Million USD | 86.173% |
| CervoMed Inc. | -7.79 Million USD | -115.441% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 90.949% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -283.924% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 87.256% |
| Moolec Science SA | 117.61 Thousand USD | 14374.418% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -633.792% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 205.602% |
| AnaptysBio, Inc. | -18.15 Million USD | 7.504% |
| Design Therapeutics, Inc. | -18.15 Million USD | 7.499% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 76.146% |
| NeurAxis, Inc. | 145.7 Thousand USD | 11622.992% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 249.475% |
| Lumos Pharma, Inc. | -28.49 Million USD | 41.077% |
| Achilles Therapeutics plc | -126.92 Million USD | 86.772% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 76.598% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -2460.353% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 19.182% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1251.409% |
| Nutriband Inc. | -251.65 Thousand USD | -6571.382% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -27.469% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -125.659% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 104.935% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 170.735% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 96.248% |
| Palisade Bio, Inc. | -12.06 Million USD | -39.178% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 88.034% |
| Beam Therapeutics Inc. | -262.72 Million USD | 93.61% |
| Neurogene Inc. | -131.95 Million USD | 87.277% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 176.957% |
| AEON Biopharma, Inc. | -4.88 Million USD | -244.037% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 95.549% |
| Sesen Bio, Inc. | -112.55 Million USD | 85.083% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 83.187% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -615.097% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 56.98% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 79.841% |
| Athira Pharma, Inc. | -88.99 Million USD | 81.136% |
| Vaccinex, Inc. | -1.28 Million USD | -1203.494% |
| HCW Biologics Inc. | 2.85 Million USD | 687.711% |
| XOMA Corporation | -29 Million USD | 42.107% |
| Nektar Therapeutics | 210.24 Million USD | 107.986% |
| Arvinas, Inc. | -313.8 Million USD | 94.65% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1134.513% |
| Merus N.V. | -192.88 Million USD | 91.296% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 127.989% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -141.986% |
| Rezolute, Inc. | -68.16 Million USD | 75.371% |
| Clene Inc. | 3.34 Million USD | 602.665% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -27.315% |
| BeyondSpring Inc. | -13.75 Million USD | -22.057% |
| Synlogic, Inc. | -6.68 Million USD | -151.144% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 1580.511% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -98.569% |
| Peak Bio, Inc. | 10.34 Million USD | 262.367% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 79.63% |
| Krystal Biotech, Inc. | -350.23 Million USD | 95.206% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 113.526% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 90.065% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -431.778% |
| MannKind Corporation | 143.89 Million USD | 111.667% |
| Ikena Oncology, Inc. | -109.15 Million USD | 84.619% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -121.754% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 49.278% |
| Gossamer Bio, Inc. | 180.35 Million USD | 109.309% |
| CohBar, Inc. | -5.93 Million USD | -183.085% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 43.563% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 467.696% |
| Legend Biotech Corporation | -949.39 Million USD | 98.232% |
| Mural Oncology plc | -255.84 Million USD | 93.438% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 152.115% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -256.406% |
| Disc Medicine, Inc. | -358.28 Million USD | 95.314% |
| Champions Oncology, Inc. | 4.81 Million USD | 448.899% |
| REGENXBIO Inc. | 54.76 Million USD | 130.655% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -6143.422% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 88.883% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -86.296% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 79.191% |
| Vaxart, Inc. | -8.24 Million USD | -103.725% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 66.542% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 86.798% |
| Cellectis S.A. | -43.85 Million USD | 61.717% |
| Longeveron Inc. | -2.9 Million USD | -477.338% |
| Repare Therapeutics Inc. | -107.85 Million USD | 84.434% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 101.734% |
| Inozyme Pharma, Inc. | 12 Million USD | 239.862% |
| Revolution Medicines, Inc. | -608.2 Million USD | 97.24% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -1264.959% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 93.667% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 88.813% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -7.299% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -2168.784% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.824% |
| Denali Therapeutics Inc. | -74.86 Million USD | 77.574% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -40.005% |
| Veru Inc. | 4.77 Million USD | 451.237% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -49.289% |
| Cingulate Inc. | 3.08 Million USD | 644.623% |
| Passage Bio, Inc. | 4.58 Million USD | 466.172% |
| Context Therapeutics Inc. | -14.44 Million USD | -16.188% |
| Exicure, Inc. | 5.84 Million USD | 387.041% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 92.712% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 57.571% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 206.998% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 71.457% |
| Nuvalent, Inc. | -335.38 Million USD | 94.994% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1068.033% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 77.459% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -88.853% |
| OmniAb, Inc. | 9.2 Million USD | 282.43% |
| Anew Medical, Inc. | 1.43 Million USD | 1272.036% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 202.486% |
| Lipocine Inc. | -4.75 Million USD | -253.111% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 84.713% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 210.229% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 66.859% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 167.447% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -149.799% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 74.495% |
| Ocugen, Inc. | -32.52 Million USD | 48.375% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 80.381% |
| Q32 Bio Inc. | -37.94 Million USD | 55.758% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -2573.408% |
| Alumis Inc. Common Stock | -13.52 Million USD | -24.096% |
| Equillium, Inc. | -22.39 Million USD | 25.022% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 34.336% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 48.542% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -6672.079% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 112.525% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 624.984% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 5211.725% |
| Dominari Holdings Inc. | 195 Thousand USD | 8709.744% |
| Edesa Biotech, Inc. | -5.26 Million USD | -218.764% |
| vTv Therapeutics Inc. | -8.91 Million USD | -88.281% |
| Bio-Techne Corporation | 267.74 Million USD | 106.27% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -3.578% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 85.783% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -99.798% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -32.709% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 93.151% |
| Nkarta, Inc. | 57.29 Million USD | 129.301% |
| BioCardia, Inc. | 212 Thousand USD | 8019.34% |
| Iterum Therapeutics plc | 13.43 Million USD | 224.937% |